# US 2023/0416269 A1 · Topical phosphoinositide 3-kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0416269 A1
- Document ID: US20230416269A1
- Status: Published application
- Kind: A1
- Application number: 18/297,698
- Filed: 2023-04-10
- Published: 2023-12-28
- Earliest claimed: 2019-02-06
- Assignees: Venthera, Inc.
- Applicants: Venthera, Inc.
- Inventors: Ahmed F. ABDEL-MAGID; Agis KYDONIEUS; Thomas ROSSI; Hock S. TAN
- Web page: https://patentgrep.com/patent/US20230416269A1

## CPC

- C07D 495/04: Ortho-condensed systems
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/38: Cellulose; Derivatives thereof
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides compounds and topical formulations including the compounds for the treatment of vascular malformations, wherein the compounds are according to formula (I): wherein subscript m, L1, R1, and L1-R1 are as described herein.

## Claims

### Claim at position 1

1-41. (canceled)

### Claim 42

A method of treating a vascular malformation through inhibiting phosphoinositide-3-kinase (PI3K) comprising administering to a subject in need thereof, an effective amount of a composition comprising a compound having formula (I):
or a hydrate, solvate, and/or a pharmaceutically acceptable salt thereof,
wherein:
subscript m is an integer from 0 to 2; and
i) L1 is —C(O)—, —C(O)O—, —C(O)S—, or —C(O)NH—; and
R1 is C1-6 alkyl, C1-6 hydroxyalkyl, C1-6 haloalkyl, C2-6 alkenyl, C6-10 aryl, C6-10 aryl-C1-6 alkyl, or C6-10 aryl-C2-6 alkenyl;
ii) L1-R1 has the formula:
wherein
the wavy line indicates the attachment to the adjacent oxygen atom in formula (I);
subscript t is an integer from 0 to 1;
subscripts p and q are independently an integer from 0 to 2;
R3 is hydrogen or a sidechain of a natural or unnatural amino acid and R4 is hydrogen, or R3 and R4 are combined to be a sidechain of a cyclic amino acid;
R5 is hydrogen or a sidechain of a natural or unnatural amino acid and R6 is hydrogen, C1-6 alkyl, or C2-6 alkenyl, or R5 and R6 are combined to be a sidechain of a cyclic amino acid; and
R7 is hydrogen, C1-6 alkyl, C2-6 alkenyl, C1-6 alkyl-C(O)—, or C2-6 alkenyl-C(O)—, or
R5 is hydrogen or a sidechain of a natural or unnatural amino acid; and
R6 and R7 are combined to form a 3-6 membered heterocycle, optionally having an additional 1-2 heteroatoms selected from O, S, and N as ring vertices; or
iii) L1 is —C(O)—; and
R1 is an aliphatic chain of a saturated fatty acid having 8-18 carbon atoms or an unsaturated fatty acid having 10-18 carbon atoms.

### Claim 43 (depends on 42)

The method of claim 42, wherein the vascular malformation is a venous malformation, an arterial malformation, an arteriovenous malformation, or a lymphatic malformation.

### Claim 44 (depends on 42)

The method of claim 42, wherein the composition is administered topically.

### Claim 45 (depends on 44)

The method of claim 44, wherein the composition is administered as a lotion, a spray, an ointment, a cream, a gel, a paste, or a patch.

### Claim 46 (depends on 42)

The method of claim 42, wherein a conversion of the compound having formula (I) to a corresponding compound having formula (IV):
after passing a skin is at least 50% over a period of 24 hours.

### Claim 47 (depends on 42)

The method of claim 42, wherein subscript m is 0 or 1.

### Claim 48 (depends on 42)

The method of claim 42, wherein L1 is —C(O)—, —C(O)O—, —C(O)S—, or —C(O)NH—; and R1 is C1-6 alkyl, C1-6 hydroxyalkyl, C1-6 haloalkyl, C2-6 alkenyl, C6-10 aryl, C6-10 aryl-C1-6 alkyl, or C6-10 aryl-C2-6 alkenyl.

### Claim 49 (depends on 42)

The method of claim 42, wherein R1 is C1-6 alkyl.

### Claim 50 (depends on 42)

The method of claim 42, wherein R1 is methyl or ethyl.

### Claim 51 (depends on 42)

The method of claim 42, wherein the compound is represented by formula (IIa):

### Claim 52 (depends on 51)

The method of claim 51, wherein R1 is C1-6 alkyl.

### Claim 53 (depends on 51)

The method of claim 51, wherein R1 is methyl or ethyl.

### Claim 54 (depends on 42)

The method of claim 42, wherein the compound is represented by the formula selected from the group consisting of:

### Claim 55 (depends on 54)

The method of claim 54, wherein R1 is C1-6 alkyl.

### Claim 56 (depends on 54)

The method of claim 54, wherein R1 is methyl or ethyl.

### Claim 57 (depends on 42)

The method of claim 42, wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 58 (depends on 42)

The method of claim 42, wherein the compound is represented by the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 59 (depends on 42)

The method of claim 42, wherein the compound is represented by the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 60 (depends on 42)

The method of claim 42, wherein the compound is represented by the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 61 (depends on 42)

The method of claim 42, wherein the compound is represented by the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 62 (depends on 46)

The method of claim 46, wherein m is 0; and the compound of formula (IV) is represented by the formula:
